Vennarecci Giovanni, Ettorre Giuseppe Maria, Boschetto Arianna, Carboni Fabio, Lepiane Pasquale, Lonardo Maria Teresa, Santoro Roberto, Santoro Eugenio
Dipartimento di Chirurgia Oncologica Divisione di Chirurgia Digestiva e dei Trapianti Istituto Regina Elena, IFO, Via Elio Chianesi, 54, 00144 Roma.
Chir Ital. 2003 Nov-Dec;55(6):797-810.
Liver transplantation for malignancies still remains a controversial issue. There is concern for tumour recurrence, poor results and waste of organs, which in the sitting of organ shortage would penalize patients with non-malignant disease. Many centers worldwide perform liver transplantation (OLT) for hepatocellular (HCC) carcinoma associated with liver cirrhosis; the results in these cases are similar to those of patients transplanted for other indications. On the contrary are very few the centers that perform OLT for tumour other than HCC. This reflects that tumours other than HCC are less common and survival is poor compared to patients transplanted for non-malignant disease. Acceptable indications for OLT in case of tumours other than HCC are liver metastases from neuroendocrine tumours and epithelioid emangio-endothelioma. However should be kept in mind that OLT may offer the sole opportunity to cure the tumour and the underlying disease in some patients while providing meaningful palliation for others. At the present the overall experience with OLT for tumours other than HCC is still not significant and the results are discouraging. There is no evidence that OLT is beneficial for non-HCC tumours. Hopefully for the next future new adjuvant and neoadjuvant therapies combined with OLT would provide improved survival. Nevertheless, long-term survivors continue to be reported suggesting that OLT may be beneficial in individual selected cases with non-HCC tumour.
恶性肿瘤的肝移植仍然是一个有争议的问题。人们担心肿瘤复发、效果不佳以及器官浪费,在器官短缺的情况下,这会对患有非恶性疾病的患者不利。全球许多中心都为伴有肝硬化的肝细胞癌(HCC)进行肝移植(OLT);这些病例的结果与因其他适应症接受移植的患者相似。相反,为除HCC之外的肿瘤进行OLT的中心很少。这反映出除HCC之外的肿瘤不太常见,与因非恶性疾病接受移植的患者相比,其生存率较低。对于除HCC之外的肿瘤,OLT可接受的适应症是神经内分泌肿瘤和上皮样血管内皮瘤的肝转移。然而,应该记住,OLT可能为一些患者提供治愈肿瘤和潜在疾病的唯一机会,同时为其他患者提供有意义的姑息治疗。目前,除HCC之外的肿瘤进行OLT的总体经验仍然不足,结果令人沮丧。没有证据表明OLT对非HCC肿瘤有益。希望在不久的将来,新的辅助和新辅助治疗与OLT相结合能提高生存率。尽管如此,仍有长期存活者的报道,这表明OLT可能对个别选定的非HCC肿瘤病例有益。